Previous Article | Next Article 
Journal of Virology, May 2001, p. 4367-4375, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4367-4375.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Human Foamy Virus Capsid Formation Requires an
Interaction Domain in the N Terminus of Gag
Joelle
Tobaly-Tapiero,
Patricia
Bittoun,
Marie-Lou
Giron,
Manuel
Neves,
Marcel
Koken,
Ali
Saïb,* and
Hugues
de Thé
CNRS UPR9051, Hôpital Saint-Louis,
Université Paris 7, 75475 Paris Cedex 10, France
Received 26 October 2000/Accepted 6 February 2001
 |
ABSTRACT |
Retroviral Gag expression is sufficient for capsid assembly, which
occurs through interaction between distinct Gag domains. Human foamy
virus (HFV) capsids assemble within the cytoplasm, although their
budding, which mainly occurs in the endoplasmic reticulum, requires the
presence of homologous Env. Yet little is known about the molecular
basis of HFV Gag precursor assembly. Using fusions between HFV Gag and
a nuclear reporter protein, we have identified a strong interaction
domain in the N terminus of HFV Gag which is predicted to contain a
conserved coiled-coil motif. Deletion within this region in an HFV
provirus abolishes viral production through inhibition of capsid assembly.
 |
INTRODUCTION |
While the genomic organization of
foamy viruses (FVs) is that of a retrovirus, they present several very
unusual features, such as the presence of infectious viral DNA in
extracellular particles or Pol expression through a specific spliced
transcript (16, 31, 33). In that sense, FVs are closely
related to pararetroviruses, such as the hepatitis B virus
(15).
For retroviruses, the Gag precursor is encoded by the full-length
genomic mRNA and is cleaved by the viral protease yielding three mature
products, the matrix, the capsid, and the nucleocapsid (13). For the so-called human foamy virus (HFV), Gag
maturation has a distinct processing pathway: the 72-kDa Gag precursor
is cleaved near its C-terminal end to yield a 68-kDa product, a
cleavage required for efficient virus infectivity (23).
Although some minor proteolytic cleavages occur within the 68-kDa
product, the classical tripartite processing of Gag does not exist in
HFV, and consequently only two high-molecular-weight proteins, of 72 and 68 kDa, are detected in infected cells or extracellular virions (14). Nucleic acid binding is performed through the
C-terminal domain of HFV Gag, which contains three
glycine/arginine-rich sequences, the GRI, -II, and -III boxes, instead
of the canonical cysteine-histidine motifs observed in other
retroviruses (27). While GRI interacts with nucleic acids
(27, 32), GRII contains a nuclear localization sequence,
targeting Gag to the nucleus (27). GRII is dispensable for
infectivity but important for reaching a high proviral load in infected
cells (20). Although GRIII is required for optimal viral
infectivity, it was not assigned a specific role as yet. Its absence in
the feline FV (FFV) and the equine FV (EFV) demonstrates its
dispensability (28, 30). Finally, Gag was shown to target
HFV preintegration complexes to the centrosome during the early steps
of infection (26). Since Gag is not myristoylated, the
basis of its membrane targeting and capsid assembly is not understood.
Retroviral Gag polyprotein expression is sufficient for capsid assembly
(13). In type C retroviruses, Gag molecules assemble into
capsids at the plasma membrane during virus budding. In type B and D
retroviruses, capsids are preassembled within the cytoplasm prior to
transport to the plasma membrane, where they exit by budding, even in
the absence of Env. Assembly of FV capsids is similar to that of type B
and D retroviruses, although their budding in the endoplasmic reticulum
(ER) or at the plasma membrane requires the presence of homologous Env,
implying that distinct intra- and intermolecular interactions control
assemby and traffic of these structures (1, 2, 12, 24).
Point mutations in Gag precursors lead to drastic changes in the
morphogenic pathways for capsid assembly or in the site of budding
(5, 11, 25).
In this report, using fusion proteins between HFV Gag and a nuclear
reporter protein (the promyelocytic protein [PML]), we identify a
Gag-Gag interaction domain in the N terminus of Gag, predicted to form
a coiled-coil motif. Deletion of this domain in an infectious HFV clone
completely abolishes viral capsid formation. Our results identify a
strong and conserved Gag-Gag interaction domain that is implicated in
capsid formation.
 |
MATERIALS AND METHODS |
Recombinant DNA.
All HFV sequences were initially derived
from pHFV13, the infectious molecular clone of HFV. Retroviral reporter
constructs (see Fig. 1A) are deletion derivatives of pHFV13, made by
digestion with either NcoI or BglII and insertion
of a PML isoform cDNA (described in reference 9) in frame
to the truncated gag gene.
The Gag expression plasmids depicted in Fig. 1C were generated by
insertion of 2.54-kb Bsu36I (Gag648), 1.77-kb
AvrII (Gag575), and 1.63-kb HinpI
(Gag511) fragments into the SmaI site of the pSG5M eukaryotic expression vector (Libin Ma, Leiden, The Netherlands). A series of Gag deletion mutants was produced by PCR with specific primers to introduce an EcoRI site at the 5' end and a
BamHI site at the 3' end. The resulting PCR product was
ligated into the EcoRI- and BamHI-digested pSG5M
expression vector. Additional Gag mutants were generated by
site-directed mutagenesis using the appropriate primers (Tables
1 and 2).
To create an HFV DNA clone with a deletion in Gag, the subclone
pHFV

EcoRI made by digestion of pHFV13 with
EcoRI and
religation
was used as a template for site-directed mutagenesis using
primers
9 and 10; the 2.8-kb
EclXI-
SwaI fragment
was then cloned back
into pHFV13 and named pHFVGag

(131-162).
Cell culture.
Cells were grown in Dulbecco's modified
Eagle's medium with 10% fetal calf serum. G418 was added at
concentrations of 1 and 0.5 mg/ml, respectively, to NIH 3T3 and BHK-21,
stably expressing Tas, provided by A. Rethwilm. COS6, an
SV40-transformed African green monkey kidney cell line, was purchased
from ATCC.
Generation of an LTR-GFP indicator cell line (FV-activated GFP
expression; FAG cells).
The GFP gene of the pGFP-C1 plasmid
(Clontech) was replaced by a green fluorescent protein (GFP) sequence
harboring the nuclear localization sequence (MAPKKKRK) of the T antigen
of simian virus 40 (SV40) at the N-terminal end. This modified GFP gene
was inserted at the NheI/BglII sites by PCR using
the following primers: direct 5'-C TAG CTA GCC
ATG GCC CCC AAG AAG AAG CGC AAG GTG AGC AAG GGC GAG
GAG-3' and reverse 5'-CAG TCC AGT GTT CTT CCT AAG CTG
GAG ATC TGA TGC CGG-3', where the nuclear localization
sequence is underlined, the GFP sequences are in bold, and the
NheI/BglII sites are in italic. The PCR product
was digested with NheI and BglII and used to
replaced the GFP gene in pGFP-C1, leading to the pGFPnls vector. The
immediate-early promoter from cytomegalovirus was removed from pGFPnls
by AseI-NheI digestion and replaced with the U3
region of the HFV long terminal repeat (LTR) obtained by PCR using the
following primers: direct 5'-G TGG ATT AAT GCC ACT AGA
AAC TAG GGA-3' and reverse 5'-C TAG CTA GCG ACG
CAG CGA GTA GT-3', where the AseI or NheI
site is underlined. This amplified product encompasses the
transcriptional initiation start of HFV in the R region at 20 bp. All
amplified products were sequenced with the ThermoSequenase sequencing
kit (Amersham) before the cloning procedures. U3GFP cell lines were
obtained after transfection of BHK-21 cells by the Lipofectin reagent
(Gibco) with pU3GFPnls, which harbors the G418 resistance gene. These
cells were maintained in the same medium supplemented with 500 µg of
G418 (Gibco)/ml. Note that the sensitivity of the FAG assay is similar
to that of the one described for the FAB cells (34).
Protein analysis.
Cells were transfected with the different
constructs using Lipofect (Gibco-BRL) as specified by the manufacturer.
Forty-eight hours posttransfection, protein expression was analyzed.
For immunofluorescence, cells were fixed with 4% paraformaldehyde at
4°C for 10 min and permeabilized with methanol at 4°C
for 5 min.
PML fusion proteins were revealed with rabbit polyclonal
or mouse
monoclonal antibodies. Proteins tagged with Flag (DYKDDDDK)
were revealed with the anti-Flag M2 monoclonal antibody (Kodak).
HFV
proteins were detected by rabbit polyclonal anti-HFV antiserum
or by
anti-Gag
382-648 antiserum raised in the laboratory.
D11 is
a mouse monoclonal antibody directed against Bet and is
used at a
dilution of 1/400.
For immunoprecipitation, 36 h posttransfection, cells were labeled
with [
35S]methionine-cysteine (75 µCi/ml, 1.175 Ci/mmol
specific activity;
Dupont NEN) for 7 h 30 min. Cells were harvested by
scraping them
into cold phosphate-buffered saline and then lysed in a
solution
containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1%
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate,
and 1 mM phenylmethylsulfonyl fluoride for 30 min at 4°C. Nuclei
were
separated from the lysate by centrifugation at 12.000 ×
g for 5 min at 4°C and lysed in
3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate
buffer
containing 0.85 M NaCl. For coimmunoprecipitation experiments,
cytoplasmic and nuclear fractions were incubated overnight at
4°C
with anti-HFV antiserum or specific anti-Gag antiserum. Protein
A-Sepharose was then added for 1 h at 4°C. Immune complexes were
centrifuged, washed four times in lysis buffer, and analyzed by
sodium
dodecyl sulfate-5 to 15% polyacrylamide gel electrophoresis,
followed
by
autoradiography.
For Western blot analyses, transiently transfected cells were lysed
directly in Laemmli buffer and proteins were resolved
by sodium dodecyl
sulfate-10% polyacrylamide gel electrophoresis.
The culture
supernatant was cleared from cellular debris and centrifuged
through a
20% sucrose cushion in a solution containing 100 mM
NaCl, 10 mM
Tris-HCl (pH 7.4), and 1 mM EDTA at 25,000 rpm for
3 h in a SW41
rotor at 4°C. The resulting pellets and cellular
viral protein
extracts were visualized by immunoblotting with
rabbit anti-Gag
antibodies and peroxidase-conjugated antibodies
and revealed by
enhanced chemiluminescence
(Amersham).
Prediction of the coiled-coil motif was performed by the COILS program
(
http://www.ch.embnet.org/software/COILS_form.html).
Electron microscopy.
Monolayers were fixed in situ with
1.6% glutaraldehyde (Taab Laboratory Equipment Ltd., Reading, United
Kingdom) in 0.1 M Sörensen phosphate buffer (pH 7.3 to 7.4) for
1 h at 4°C. Cells were scraped from their plastic substratum and
centrifuged. The resulting pellets were successively postfixed with 2%
aqueous osmium tetroxide for 1 h at room temperature, dehydrated
in ethanol, and embedded in Epon. Ultrathin sections were collected on
200-mesh copper grids coated with Formvar and carbon and stained with
uranyl acetate and lead citrate prior to being observed with a Philips 400 transmission electron microscope at 80 kV; magnification, ×2,800
to ×36,000.
 |
RESULTS |
HFV Gag-Gag interaction.
During the course of our studies
aimed at characterizing the encapsidation signal of HFV, we generated
HFV reporter constructs in which a PML cDNA (9) was
substituted for the pol, env, and bel/tas sequences (Fig. 1A). The PML gene was
originally identified through its fusion to the RAR
gene in the
t(15;17) translocation found in acute promyelocytic
leukemia. PML has a speckled nuclear expression pattern as a
consequence of its localization onto nuclear bodies (NBs), structures
belonging to the nuclear matrix (15). This distinct
speckled localization of PML makes it an attractive reporter, since
very low levels of expression are readily detected by
immunofluorescence (IF). In the Gag-PML retroviral construct, PML is
expressed from the LTR promoter as a Gag-PML fusion protein that
retains the first 382 amino acids of Gag (Fig. 1A). Since expression of
this Gag382-PML protein is dependent on HFV LTR activity,
we transiently transfected NIH 3T3-Tas cells, which stably express the
HFV transactivator Tas (originally called Bel1). Our PML antibodies do
not detect the endogenous PML protein in NIH 3T3, COS6, or BHK-21
cells, and therefore, expression of transfected Gag382-PML
was monitored by IF. In transfected cells, antibodies to PML detect the
Gag-PML fusion onto NBs (Fig. 1B, panel a), demonstrating that fusion
to Gag does not alter the NB targeting of PML and therefore its
folding.



View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Schematic representation of the HFV provirus and
Gag-PML retroviral constructs. Parts of the gag gene and the
entire pol and env genes were replaced by the PML
cDNA. (B) IF analysis demonstrating delocalization of Gag-PML fusion
after transfection of the full-length infectious HFV molecular clone
(pHFV13) or Gag-expressing vector (pGag648). NIH 3T3 cells
stably expressing Tas (panels a and b) or COS6 (panels c and d) were
transfected and analyzed by IF with the indicated antibodies. (C)
Localization of the Gag177-PML construct upon expression of
Gag648 or derived deletion mutants, followed by IF using an
anti-PML antiserum. The locations of the three glycine/arginine-rich
boxes (GRI, -II, and -III) are indicated by shaded regions. The arrow
points to the viral protease cleavage site. The staining was diffuse
nuclear (DN) or associated to NB.
|
|
In attempts to pseudotype the Gag-PML construct with HFV structural
proteins, we have cotransfected this construct with an
infectious
molecular HFV clone, pHFV13. To our surprise, coexpression
with pHFV13
led to diffuse nuclear PML staining (Fig.
1B, panel
b). In contrast to
several other viruses (
4), HFV does not
alter the
structure of NBs and consequently the location of endogenous
or
transfected PML (data not shown). Hence, our observations suggested
that HFV infection specifically alters the NB targeting of the
Gag
382-PML through interactions with its Gag moiety. When
Gag-PML
fusion proteins were expressed from an SV40 promoter rather
than
from the HFV LTR, a similar HFV-induced delocalization was
observed,
allowing the subsequent use of naive cells rather than
Tas-expressing
ones. Since a similar HFV-induced delocalization was
observed
with a shorter Gag
177-PML (data not shown), the
N-terminal region
of Gag is required for delocalization of Gag-PML
fusion
proteins.
To identify the HFV gene product(s) responsible for the altered
localization of Gag-PML, we cotransfected Gag
177-PML with
expression vectors encoding the full-length HFV Gag
648,
Env, or
Bet proteins. Delocalization of the Gag
177-PML
fusion was exclusively
obtained following expression of the
Gag
648 protein (Fig.
1B,
panels c and d), suggestive for
the existence of specific Gag-Gag
interactions.
During HFV infection, the Gag precursor is detected both in the nucleus
and in the cytoplasm of infected cells, as a p72/p68
doublet. The C
terminus of Gag
648 contains glycine/arginine-rich
sequences
(GR boxes) involved in nucleic acid binding (GRI) and
nuclear
localization (GRII) (Fig.
1C). To determine whether the
GR boxes are
required for Gag
177-PML delocalization, GR deletion
mutants
were derived from the Gag
648 expression vector. As
summarized
in Fig.
1C, all constructs harboring GRII delocalized
Gag
177-PML
from nuclear bodies, even in the absence of GRI.
These results
demonstrate that Gag-PML delocalization by Gag requires
the presence
of Gag residues 511 to 575 (including GRII), which likely
bind
distinct nuclear components preventing the NB targeting of the
Gag-PML fusion protein. Interaction between this region and putative
nuclear components is necessarily stronger than that driving Gag-PML
onto NBs. This nuclear anchor, which remains to be characterized,
together with the nuclear localization signal function harbored
by
GRII, is likely to play a role in the nuclear accumulation
of
Gag.
Mapping of sequences involved in Gag-Gag interaction.
To
determine which part of Gag interacts with Gag177-PML
fusion, three constructs were generated, expressing Gag from amino acids 1 to 203, 203 to 441, and 437 to 648, all tagged with a C-terminal Flag sequence. This particular partition of Gag was made
according to protease cleavage sites that were initially predicted
(18). COS6 cells were transfected with these expression vectors together with Gag177-PML. Only the construct
expressing Gag203 led to NB-associated anti-Flag staining
(Fig. 2A and data not shown), demonstrating the
existence of an interaction between Gag203 and
Gag177-PML.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Gag-Gag interaction involves the N-terminal domain. (A)
IF analysis. Transfected COS6 cells were subjected to double
immunofluorescence labeling with the mouse monoclonal anti-Flag M2
(revealed by fluorescein isothiocyanate) and rabbit polyclonal anti-PML
antibodies (revealed with Texas red). (B) Coimmunoprecipitation assay.
[S35]methionine-cysteine-labeled viral proteins were
immunoprecipitated from cytoplasmic and nuclear extracts with the
indicated antibodies. (C) Interaction of Gag mutants with
Gag177-PML onto NBs was assessed by IF using the anti-Flag
M2 antibody: the plus sign corresponds to an efficiency similar to that
of Gag203, and the minus sign corresponds to an absence of
interaction.
|
|
Gag-Gag interaction was also assessed by biochemical analyses. In these
experiments, Gag
575 alone (which harbors both GRI
and GRII
boxes) was used rather than Gag
177-PML, since PML is
a
nuclear matrix protein whose extraction requires stringent conditions
that would disrupt protein complexes. COS6 cells were transfected
with
expression vectors for Gag
203, Gag
575, or both;
labeled with
[
35S]methionine-cysteine; and separated into
cytoplasmic and nuclear
fractions. Cell extracts were then
immunoprecipitated with either
an antibody that recognizes all HFV
proteins or one specific antiserum
directed against the C-terminal
region of Gag (amino acids 382
to 648) interacting solely with
Gag
575 and not with Gag
203, as
shown in the
last lane of Fig.
2B. In both the cytoplasmic and
the nuclear
fractions, Gag
203 was readily coimmunoprecipitated
with
Gag
575 using the antibody directed against the C-terminal
moiety of Gag (Fig.
2B). This implied that a significant fraction
of
the two proteins interacts and confirmed the existence of an
interaction domain in the N terminus of HFV Gag. Moreover, this
experiment proved that such an interaction occurs outside of a
Gag-PML
fusion protein
context.
To precisely map the sequences within Gag
203 that are
implicated in Gag-Gag interaction, Flag-Gag
203 deletion
mutants were
generated and tested for their ability to interact with
Gag
177-PML,
using the same assay as that shown in Fig.
2A.
While deletion
of residues 123 to 203 abolished Gag-Gag interaction,
Gag
123-203 totally colocalized with Gag
177-PML
onto NBs (Fig.
2C), as already
was observed with Gag
203
(Fig.
2A), suggesting that the association
between both molecules is
stable. These results implied that the
region encompassing amino acids
123 to 203 mediates Gag-Gag
interaction.
Careful examination of the HFV domain between amino acids 123 and 203 revealed the presence of regularly spaced hydrophobic
residues (Fig.
3A), suggestive for the presence of a
coiled-coil
motif, which was confirmed by analysis of this region with
the
COILS program (Fig.
3B). Although FV Gag proteins show little
similarity (
29), alignment of this region from six foamy
virus
isolates (HFV, simian FV type 3, simian FV type 1, FFV, bovine
FV
[BFV], and EFV) revealed the conservation of this putative
coiled-coil motif in all but the two nonprimate FVs, BFV and EFV
(Fig.
3B).


View larger version (35K):
[in this window]
[in a new window]
|
FIG. 3.
(A) Multiple amino acids alignment shows that
hydrophobic residues are conserved among FVs. Conserved residues are
shown in boldface. (B) Prediction of coiled-coil motifs in N termini of
Gag proteins from FVs by the COILS program (Matrix: MTIDK, weight of
2.5 for position N).
|
|
Biological role of the Gag-Gag interaction.
Based on the
prediction of the COILS program, we generated a deletion spanning
residues 131 to 162 in Gag203. Since this deletion abolished its interaction with Gag177-PML on NBs, a similar
mutation was introduced into the infectious pHFV13 clone, leading to
pHFVGag
(131-162). This mutant and the wild-type proviral clones
were transfected in Tas-expressing BHK-21 cells. Two days after
transfection, virus production was determined by exposing BHK-21 GFP
indicator cells (see Materials and Methods) to cell supernatants from
these transfected cells. Fluorescence observed at 24 h
postinfection revealed that no infectious virus was produced with the
Gag mutant clone (<0.5 fluorescent-cell-forming units [FCFU]/ml),
whereas the wild-type provirus led to significant viral production
(9.3 × 104 FCFU/ml). Trans-complementation
of the mutant virus clone with a full-length HFV Gag648
expression vector [pHFVGag
(131-162)+pGag648] partially restored viral infectivity (3 × 104
FCFU/ml) as expected (values are averaged from three independent experiments) (35). Hence, Gag-Gag interaction is essential
for viral infectivity.
To test whether the lack of infectivity of the HFV Gag mutant clone is
due to either impairment of capsid formation, virus
particle egress, or
release of a defective virus, supernatants
from transfected cells were
centrifuged through a sucrose cushion
and the resulting pellets were
analyzed by Western blotting (WB)
and compared to the corresponding
cellular extracts. Cell extracts
from wild-type or mutant
provirus-transfected cells showed no
major difference in the level of
intracellular p72/p68 Gag expression;
anti-Bet antibodies (D11) also
revealed similar levels of p62
Bet in all transfected cell extracts,
demonstrating that, as expected,
deletion of Gag did not impair viral
gene expression (Fig.
4A).
Strikingly, when the viral
pellets were analyzed by WB, no Gag
protein was
detected in the supernatant of mutant transfected
cells, showing that
this mutation abolished virus release (Fig.
4). Cotransfection of the
mutant HFV clone with a full-length
Gag-expressing vector partially
restored virus release to the
supernatant as expected. Yet in that
case, a p68 protein was mainly
detected. It is most likely that this
represents the cleaved p72
fragment rather than the full-size Gag
polyprotein derived from
the mutated virus. The smaller amount of Gag
(and hence of virus)
retrieved in that case indicates that the deleted
Gag polyprotein
has some dominant-negative effects on capsid assembly,
suggestive
for the existence of other interaction interfaces in Gag as
reported
previously (
3,
10). One possible explanation for
the almost
exclusive presence of p68 could then be that Gag

(131-163) selectively
binds p72 Gag.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 4.
(A) Western blot analysis of cell extracts and virus
pellets from cells transfected either with pHFVGag (131-162) or with
pHFV13 clones. Antibodies used are either a rabbit polyclonal
anti-Gag382-648 antibody or a monoclonal anti-Bet
antiserum (D11). Mutation of Gag completely abolishes virus
release from transfected cells, whereas cotransfection with a wild-type
Gag (pGag648) partially restores virus production. (B)
Electron micrographs of BHK-21 cells 48 h after transfection with
pHFV13 (panels a and c) and pHFVGag (131- 162) trans-complemented with Gag648
(panels b and d). Images represent budding of virus particles (panels a
and b) or clusters of capsids (panels c and d). The bars correspond to
200 nm (a and b) or 400 nm (c and d).
|
|
The absence of viruses in the supernatant of
pHFVGag

(131-162)-transfected cells could be due to the impairment
of capsid
formation or of virus exit. Hence, cells transfected with
wild-type
or mutant proviral DNAs were analyzed by electron microscopy.
In HFV-expressing cells, capsids and budding viruses were observed
in a
large number of cells. In contrast, in cells transfected
by the virus
harboring the mutated Gag, no viral capsid could
be observed, despite a
similar transfection efficiency. Again,
trans-complementation of the mutant virus with a
Gag-expressing
vector (Gag
648) led to the appearance of
viral particles (Fig.
4B). Therefore, Gag-Gag interaction through its
131 to 162 amino
acid domain is absolutely required for capsid
formation.
 |
DISCUSSION |
This report identifies a strong Gag-Gag interaction domain at the
N terminus of HFV Gag that is required for intracellular capsid
assembly. This interaction domain was first demonstrated by the
analysis of nuclear fluorescence patterns, diffuse or onto NBs, of Gag
molecules and derivative mutants in the presence of a Gag-PML fusion
protein. Interaction was further confirmed by coimmunoprecipitation
experiments. Finally, we showed using different approaches that the
domain spanning residues 131 to 162 was necessary for the formation of
viral capsids.
Interaction and subsequent multimerization of Gag molecules play a
crucial role in capsid assembly (13). Depending on the virus, multiple strong dimerization interfaces have been described along the Gag protein, especially within the matrix, the C-terminal globular domain of the capsid, and the nucleocapsid sequence (3, 8). Multiple and sequential interactions of Gag molecules allow the precise concentration and folding of precursors to form capsids. While the mechanism of capsid assembly has been intensively studied for
other retroviruses, little is known about FV capsid formation, in
particular on Gag domains involved in this step of the viral cycle.
Complementation analyses of Rous sarcoma virus and HFV Gag revealed the
presence of two putative interaction domains (the I domains) in the C
terminus of HFV Gag overlapping the GRI box (3). Since we
have shown that the mutated clone pHFVGag
(131-162) is defective for
capsid assembly, these I domains alone do not seem to be sufficient to
form viral capsids. More recently, Eastman et al. have reported that
mutation of a conserved Arg residue at position 50 in HFV Gag prevents
formation of extracellular virions, presumably by disrupting capsid
assembly. This amino acid lies within a motif resembling the
morphogenetic signal of the type D retrovirus, Mason-Pfizer monkey
virus (5, 25, 28). The sequential involvement of these
characterized determinants (I domains, the Gag region between residues
131 to 162, and the Arg50 residue), which could be necessary to trigger
capsid assembly, remains to be elucidated.
Here we show that the region mediating Gag-Gag interaction contains a
conserved motif which could form a coiled coil (19). This
sequence appears to function as a whole, since point mutants in the
conserved residues of the putative coiled coil failed to abolish the
interaction (data not shown). Note in that respect that deletions that
were similar in size did not abrogate capsid formation in other viruses
(11, 36). Such a domain was found in primate and
nonprimate FVs. However, in BFV and EFV, the probability of forming a
coiled coil is low. Interestingly, these two viruses also lack the ER
retrieval dilysine motif in the Env cytoplasmic tails, which is
responsible for HFV budding at the ER. In line with this observation,
EFV was shown to bud mainly at the plasma membrane (28).
The assay outlined here to detect protein-protein interactions in vivo
using NB targeting of PML as an end point could be of general interest.
Indeed, using NB targeting of a protein through interaction with
another protein fused to PML can be a sensitive way to demonstrate
protein-protein interaction within the nucleus. It can also be used to
compare the strengths of different intranuclear targeting signals.
For exogenous retroviruses, cellular expression of Gag is sufficient
for capsid assembly and release of virus-like particles. FV assembly
and egress are unique among the retroviral family (17). In
particular, budding of preassembled viral capsids requires the
expression of the cognate FV envelope, reminiscent of the hepadnavirus
assembly pathway. Although the results presented in this
report bring new insights into the formation of FV capsids, several
points remain to be elucidated, one of the most intriguing being the
targeting of Gag to the membranes of the ER. For intracisternal A type
particles, which, like HFV, lack an N-terminal myristoylation signal, a
stretch of hydrophobic amino acids at the N terminus of Gag directs
virus budding to the ER (21). However, it has already been
demonstrated that this is not the case for HFV capsids, which never bud
at any internal membrane in the absence of Env (12).
Whether the Gag domain characterized in this study is involved in
Gag-Env interactions remains to be investigated.
 |
ACKNOWLEDGMENTS |
Ali Saïb and Hugues de Thé should be considered
senior coauthors.
We warmly thank J. Lasneret, F. Rocher, and A. Janin for electron
microscopy studies and LPH (Laboratoire Photo de l'Institut d'Hématologie) for the photographic work.
H. de Thé is supported by Université Paris 7 and Assistance Publique.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: CNRS UPR9051,
Hôpital Saint-Louis, 1, Ave. Claude Vellefaux, 75475 Paris Cedex
10, France. Phone: 33.1.53.72.40.96. Fax: 33.1.53.72.40.90. E-mail: alisaib{at}infobiogen.fr.
 |
REFERENCES |
| 1.
|
Baldwin, D. N., and M. L. Linial.
1998.
The roles of Pol and Env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 2.
|
Baldwin, D. N., and M. L. Linial.
1999.
Proteolytic activity, the carboxy terminus of Gag, and the primer binding site are not required for Pol incorporation into foamy virus particles.
J. Virol.
73:6387-6393[Abstract/Free Full Text].
|
| 3.
|
Bowzard, J. B.,
R. P. Bennett,
N. K. Krishna,
S. M. Ernst,
A. Rein, and J. W. Wills.
1998.
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue.
J. Virol.
72:9034-9044[Abstract/Free Full Text].
|
| 4.
|
Chelbi-Alix, M. K.,
F. Quignon,
L. Pelicano,
M. H. M. Koken, and H. de Thé.
1998.
Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein.
J. Virol.
72:1043-1051[Abstract/Free Full Text].
|
| 5.
|
Choi, G.,
S. Park,
B. Choi,
S. Hong,
J. Lee,
E. Hunter, and S. S. Rhee.
1999.
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein.
J. Virol.
73:5431-5437[Abstract/Free Full Text].
|
| 6.
|
Conte, M. R.,
M. Klikova,
E. Hunter,
T. Ruml, and S. Matthews.
1997.
The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly.
EMBO J.
16:5819-5826[CrossRef][Medline].
|
| 7.
|
Conte, M. R., and S. Matthews.
1998.
Retroviral matrix proteins: a structural perspective.
Virology
246:191-198[CrossRef][Medline].
|
| 8.
|
Dawson, L., and X. F. Yu.
1998.
The role of nucleocapsid of HIV-1 in virus assembly.
Virology
251:141-157[CrossRef][Medline].
|
| 9.
|
de The, H.,
C. Lavau,
A. Marchio,
C. Chomienne,
L. Degos, and A. Dejean.
1991.
The PML-RAR alpha fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR.
Cell
66:675-684[CrossRef][Medline].
|
| 10.
|
Eastman, S. W.,
S. Benki,
D. N. Baldwin, and M. L. Linial.
2000.
Domains of foamy virus Gag involved in particle assembly and morphogenesis, p. 114.
In
Proceedings of the 2000 Cold Spring Harbor Meeting on Retroviruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 11.
|
Facke, M.,
A. Janetzko,
R. L. Shoeman, and H. G. Krausslich.
1993.
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.
J. Virol.
67:4972-4980[Abstract/Free Full Text].
|
| 12.
|
Fischer, N.,
M. Heinkelein,
D. Lindemann,
J. Enssle,
C. Baum,
E. Werder,
H. Zentgraf,
J. G. Muller, and A. Rethwilm.
1998.
Foamy virus particle formation.
J. Virol.
72:1610-1615[Abstract/Free Full Text].
|
| 13.
|
Freed, E. O.
1998.
HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology
251:1-15[CrossRef][Medline].
|
| 14.
|
Giron, M. L.,
S. Colas,
J. Wybier,
F. Rozain, and R. Emanoil-Ravier.
1997.
Expression and maturation of human foamy virus Gag precursor polypeptides.
J. Virol.
71:1635-1639[Abstract].
|
| 15.
|
Koken, M. H.,
F. Puvion-Dutilleul,
M. C. Guillemin,
A. Viron,
G. Linares-Cruz,
N. Stuurman,
L. de Jong,
C. Szostecki,
F. Calvo,
C. Chomienne, et al.
1994.
The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.
EMBO J.
13:1073-1083[Medline].
|
| 16.
|
Lecellier, C., and A. Saib.
2000.
Foamy viruses: between pararetroviruses and retroviruses.
Virology
271:1-8[CrossRef][Medline].
|
| 17.
|
Linial, M. L.
1999.
Foamy viruses are unconventional retroviruses.
J. Virol.
73:1747-1755[Free Full Text].
|
| 18.
| Lochelt, M., and R. Flugel. The molecular biology
of human and primate spuma retroviruses, p. 239-292. In J. Levy (ed.), The Retroviridae. Plenum Press, New York, N.Y.
|
| 19.
|
Lupas, A.
1997.
Predicting coiled-coil regions in proteins.
Curr. Opin. Struct. Biol.
7:388-393[CrossRef][Medline].
|
| 20.
|
Meiering, C. D.,
K. E. Comstock, and M. L. Linial.
2000.
Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells.
J. Virol.
74:1718-1726[Abstract/Free Full Text].
|
| 21.
|
Mietz, J. A.,
Z. Grossman,
K. K. Lueders, and E. L. Kuff.
1987.
Nucleotide sequence of a complete mouse intracisternal A-particle genome: relationship to known aspects of particle assembly and function.
J. Virol.
61:3020-3029[Abstract/Free Full Text].
|
| 22.
|
Morikawa, Y.,
W. H. Zhang,
D. J. Hockley,
M. V. Nermut, and I. M. Jones.
1998.
Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17.
J. Virol.
72:7659-7663[Abstract/Free Full Text].
|
| 23.
|
Pfrepper, K. I.,
M. Lochelt,
H. R. Rackwitz,
M. Schnolzer,
H. Heid, and R. M. Flugel.
1999.
Molecular characterization of proteolytic processing of the Gag proteins of human spumavirus.
J. Virol.
73:7907-7911[Abstract/Free Full Text].
|
| 24.
|
Pietschmann, T.,
M. Heinkelein,
M. Heldmann,
H. Zentgraf,
A. Rethwilm, and D. Lindemann.
1999.
Foamy virus capsids require the cognate envelope protein for particle export.
J. Virol.
73:2613-2621[Abstract/Free Full Text].
|
| 25.
|
Rhee, S. S., and E. Hunter.
1990.
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus.
Cell
63:77-86[CrossRef][Medline].
|
| 26.
|
Saïb, A.,
F. Puvion-Dutilleul,
M. Schmid,
J. Périès, and H. de Thé.
1997.
Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step.
J. Virol.
71:1155-1161[Abstract].
|
| 27.
|
Schliephake, A. W., and A. Rethwilm.
1994.
Nuclear localization of foamy virus Gag precursor protein.
J. Virol.
68:4946-4954[Abstract/Free Full Text].
|
| 28.
|
Tobaly-Tapiero, J.,
P. Bittoun,
M. Neves,
M. Guillemin,
C. Lecellier,
F. Puvion-Dutilleul,
B. Gicquel,
S. Zientara,
M. L. Giron,
H. de Thé, and A. Saïb.
2000.
Isolation and characterization of an equine foamy virus (EFV).
J. Virol.
74:4064-4073[Abstract/Free Full Text].
|
| 29.
|
Wang, G., and M. J. Mulligan.
1999.
Comparative sequence analysis and predictions for the envelope glycoproteins of foamy viruses.
J. Gen. Virol.
80:245-254[Abstract].
|
| 30.
|
Winkler, I.,
J. Bodem,
L. Haas,
M. Zemba,
H. Delius,
R. Flower,
R. M. Flugel, and M. Lochelt.
1997.
Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses.
J. Virol.
71:6727-6741[Abstract].
|
| 31.
|
Yu, S. F.,
D. N. Baldwin,
S. R. Gwynn,
S. Yendapalli, and M. L. Linial.
1996.
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.
Science
271:1579-1582[Abstract].
|
| 32.
|
Yu, S. F.,
K. Edelmann,
R. K. Strong,
A. Moebes,
A. Rethwilm, and M. L. Linial.
1996.
The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains.
J. Virol.
70:8255-8262[Abstract].
|
| 33.
|
Yu, S. F.,
M. D. Sullivan, and M. L. Linial.
1999.
Evidence that the human foamy virus genome is DNA.
J. Virol.
73:1565-1572[Abstract/Free Full Text].
|
| 34.
|
Yu, S. F., and M. L. Linial.
1993.
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.
J. Virol.
67:6618-6624[Abstract/Free Full Text].
|
| 35.
|
Zemba, M.,
T. Wilk,
T. Rutten,
A. Wagner,
R. F. Flugel, and M. Lochelt.
1998.
The carboxy-terminal p3Gag domain of the human foamy virus Gag precursor is required for efficient virus infectivity.
Virology
247:7-13[CrossRef][Medline].
|
| 36.
|
Zhang, W. H,
D. J. Hockley,
M. V. Nermut,
Y. Morikawa, and I. M. Jones.
1996.
Gag-Gag interactions in the C-terminal domain of human immunodeficiency virus type 1 p24 capsid antigen are essential for Gag particle assembly.
J. Gen. Virol.
77:743-751[Abstract/Free Full Text].
|
Journal of Virology, May 2001, p. 4367-4375, Vol. 75, No. 9
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.9.4367-4375.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mannigel, I., Stange, A., Zentgraf, H., Lindemann, D.
(2007). Correct Capsid Assembly Mediated by a Conserved YXXLGL Motif in Prototype Foamy Virus Gag Is Essential for Infectivity and Reverse Transcription of the Viral Genome. J. Virol.
81: 3317-3326
[Abstract]
[Full Text]
-
Cartellieri, M., Herchenroder, O., Rudolph, W., Heinkelein, M., Lindemann, D., Zentgraf, H., Rethwilm, A.
(2005). N-Terminal Gag Domain Required for Foamy Virus Particle Assembly and Export. J. Virol.
79: 12464-12476
[Abstract]
[Full Text]
-
Lehmann-Che, J., Giron, M.-L., Delelis, O., Lochelt, M., Bittoun, P., Tobaly-Tapiero, J., de The, H., Saib, A.
(2005). Protease-Dependent Uncoating of a Complex Retrovirus. J. Virol.
79: 9244-9253
[Abstract]
[Full Text]
-
Schiffer, C., Lecellier, C.-H., Mannioui, A., Felix, N., Nelson, E., Lehmann-Che, J., Giron, M.-L., Gluckman, J. C., Saib, A., Canque, B.
(2004). Persistent Infection with Primate Foamy Virus Type 1 Increases Human Immunodeficiency Virus Type 1 Cell Binding via a Bet-Independent Mechanism. J. Virol.
78: 11405-11410
[Abstract]
[Full Text]
-
Petit, C., Giron, M.-L., Tobaly-Tapiero, J., Bittoun, P., Real, E., Jacob, Y., Tordo, N., de The, H., Saib, A.
(2003). Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J. Cell Sci.
116: 3433-3442
[Abstract]
[Full Text]
-
Verschoor, E. J., Langenhuijzen, S., van den Engel, S., Niphuis, H., Warren, K. S., Heeney, J. L.
(2003). Structural and Evolutionary Analysis of an Orangutan Foamy Virus. J. Virol.
77: 8584-8587
[Abstract]
[Full Text]
-
Lecellier, C.-H., Vermeulen, W., Bachelerie, F., Giron, M.-L., Saib, A.
(2002). Intra- and Intercellular Trafficking of the Foamy Virus Auxiliary Bet Protein. J. Virol.
76: 3388-3394
[Abstract]
[Full Text]